Evidence map›Paper›PMID 38890276›Full record

ArticleNature communications2024

Enhanced eMAGE applied to identify genetic factors of nuclear hormone receptor dysfunction via combinatorial gene editing.

Peter N Ciaccia, Zhuobin Liang, Anabel Y Schweitzer, Eli Metzner, Farren J Isaacs

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Peter N Ciaccia *Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT, 06520, USA.
Zhuobin Liang *Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT, 06520, USA. zbliang@szbl.ac.cn.
Anabel Y SchweitzerDepartment of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT, 06520, USA.
Eli MetznerDepartment of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT, 06520, USA.ORCID 0000-0002-8957-9068
Farren J IsaacsDepartment of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT, 06520, USA. farren.isaacs@yale.edu.ORCID 0000-0001-8615-8236

Funding

Systems analysis of phenotypic switch in control of cancer invasionU54CA209992 · NCI · YALE UNIVERSITY · PI LEVCHENKO, ANDRE · 2016 to 2021
$10.1M
National Science Foundation (NSF) IOS-1923321NCI NIH HHS U54 CA209992
6 · The paper itself

Abstract

Technologies that generate precise combinatorial genome modifications are well suited to dissect the polygenic basis of complex phenotypes and engineer synthetic genomes. Genome modifications with engineered nucleases can lead to undesirable repair outcomes through imprecise homology-directed repair, requiring non-cleavable gene editing strategies. Eukaryotic multiplex genome engineering (eMAGE) generates precise combinatorial genome modifications in Saccharomyces cerevisiae without generating DNA breaks or using engineered nucleases. Here, we systematically optimize eMAGE to achieve 90% editing frequency, reduce workflow time, and extend editing distance to 20 kb. We further engineer an inducible dominant negative mismatch repair system, allowing for high-efficiency editing via eMAGE while suppressing the elevated background mutation rate 17-fold resulting from mismatch repair inactivation. We apply these advances to construct a library of cancer-associated mutations in the ligand-binding domains of human estrogen receptor alpha and progesterone receptor to understand their impact on ligand-independent autoactivation. We validate that this yeast model captures autoactivation mutations characterized in human breast cancer models and further leads to the discovery of several previously uncharacterized autoactivating mutations. This work demonstrates the development and optimization of a cleavage-free method of genome editing well suited for applications requiring efficient multiplex editing with minimal background mutations.

Indexed as

CRISPR-Cas SystemsGene EditingMutationSaccharomyces cerevisiaeBreast NeoplasmsDNA Mismatch RepairEstrogen Receptor alphaFemaleHumansReceptors, ProgesteroneESR1 protein, humanEstrogen Receptor alphaReceptors, Progesterone

Identifiers

PMID38890276
PMCPMC11189492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.